Adrenocortical carcinoma overview

Jump to: navigation, search

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma overview On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma overview

CDC on Adrenocortical carcinoma overview

Adrenocortical carcinoma overview in the news

Blogs on Adrenocortical carcinoma overview</small>

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Adrenocortical carcinoma, also adrenal cortical carcinoma (ACC) and adrenal cortex cancer, is an aggressive cancer originating in the cortex (steroid hormone-producing tissue) of the adrenal gland. Adenocortical carcinoma is remarkable for the many hormonal syndromes which can occur in patients with steroid hormone-producing ("functional") tumors, including Cushing's syndrome, Conn syndrome, virilization, and feminization. Adrenocortical carcinoma has often invaded nearby tissues or metastasized to distant organs at the time of diagnosis, and the overall 5-year survival rate is only 20-35%.

References


Linked-in.jpg